How to Manage the Infectious Risk under Anti-TNF in Inflammatory Bowel Disease

E-ISSN： 1873-5592|11|2|198-218

ISSN： 1389-4501

Source： Current Drug Targets, Vol.11, Iss.2, 2010-02, pp. : 198-218

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-TNF Antibodies in Inflammatory Bowel Disease: Do We Finally Know How it Works?

Current Drug Targets, Vol. 14, Iss. 12, 2013-11 ,pp. : 1421-1432

Bentham Science Publishers

Access to resources Recommend Favorite

“How to Manage Loss of Response to Anti-TNF in Crohn's Disease?”

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 152-155

Bentham Science Publishers

Access to resources Recommend Favorite

Utility of Measuring Serum Concentrations of Anti-TNF Agents and Anti-Drug Antibodies in Inflammatory Bowel Disease

Current Drug Metabolism, Vol. 12, Iss. 6, 2011-07 ,pp. : 594-598

Bentham Science Publishers

Access to resources Recommend Favorite

Measurement of Anti-TNF Agents and Anti-Drug Antibodies Serum Levels in Patients with Inflammatory Bowel Disease

Current Drug Metabolism, Vol. 15, Iss. 9, 2014-11 ,pp. : 875-881

Bentham Science Publishers

Access to resources Recommend Favorite

Anti-TNF Antibody Therapy for Inflammatory Bowel Disease During Pregnancy: A Clinical Review

Current Drug Targets, Vol. 11, Iss. 2, 2010-02 ,pp. : 234-241

Bentham Science Publishers

Access to resources Recommend Favorite